BioXcel TherapeuticsBTAI
About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Employees: 37
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
325% more call options, than puts
Call options by funds: $17K | Put options by funds: $4K
5.75% less ownership
Funds ownership: 17.27% [Q4 2024] → 11.52% (-5.75%) [Q1 2025]
38% less funds holding
Funds holding: 48 [Q4 2024] → 30 (-18) [Q1 2025]
76% less capital invested
Capital invested by funds: $3.21M [Q4 2024] → $770K (-$2.44M) [Q1 2025]
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
96% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 24
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Rodman & Renshaw Elemer Piros | 4,543%upside $65 | Buy Initiated | 19 Mar 2025 |
Financial journalist opinion









